Is ArriVent BioPharma (NASDAQ:AVBP) In A Good Position To Deliver On Growth Plans?
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although software-as-a-service business Salesforce.com lost money for years while it grew recurring revenue, if you held shares since 2005, you'd have done very well indeed. But while history lauds those rare successes, those that fail are often forgotten; who remembers Pets.com?
So, the natural question for ArriVent BioPharma (NASDAQ:AVBP) shareholders is whether they should be concerned by its rate of cash burn. For the purposes of this article, cash burn is the annual rate at which an unprofitable company spends cash to fund its growth; its negative free cash flow. We'll start by comparing its cash burn with its cash reserves in order to calculate its cash runway.
We've discovered 2 warning signs about ArriVent BioPharma. View them for free.
A company's cash runway is the amount of time it would take to burn through its cash reserves at its current cash burn rate. When ArriVent BioPharma last reported its March 2025 balance sheet in May 2025, it had zero debt and cash worth US$176m. Importantly, its cash burn was US$120m over the trailing twelve months. Therefore, from March 2025 it had roughly 18 months of cash runway. Importantly, analysts think that ArriVent BioPharma will reach cashflow breakeven in 4 years. That means unless the company reduces its cash burn quickly, it may well look to raise more cash. Depicted below, you can see how its cash holdings have changed over time.
View our latest analysis for ArriVent BioPharma
ArriVent BioPharma didn't record any revenue over the last year, indicating that it's an early stage company still developing its business. Nonetheless, we can still examine its cash burn trajectory as part of our assessment of its cash burn situation. The skyrocketing cash burn up 108% year on year certainly tests our nerves. It's fair to say that sort of rate of increase cannot be maintained for very long, without putting pressure on the balance sheet. While the past is always worth studying, it is the future that matters most of all. So you might want to take a peek at how much the company is expected to grow in the next few years.
Given its cash burn trajectory, ArriVent BioPharma shareholders may wish to consider how easily it could raise more cash, despite its solid cash runway. Companies can raise capital through either debt or equity. One of the main advantages held by publicly listed companies is that they can sell shares to investors to raise cash and fund growth. By comparing a company's annual cash burn to its total market capitalisation, we can estimate roughly how many shares it would have to issue in order to run the company for another year (at the same burn rate).
Since it has a market capitalisation of US$684m, ArriVent BioPharma's US$120m in cash burn equates to about 17% of its market value. As a result, we'd venture that the company could raise more cash for growth without much trouble, albeit at the cost of some dilution.
On this analysis of ArriVent BioPharma's cash burn, we think its cash runway was reassuring, while its increasing cash burn has us a bit worried. Shareholders can take heart from the fact that analysts are forecasting it will reach breakeven. We don't think its cash burn is particularly problematic, but after considering the range of factors in this article, we do think shareholders should be monitoring how it changes over time. On another note, ArriVent BioPharma has 2 warning signs (and 1 which can't be ignored) we think you should know about.
Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of companies with significant insider holdings, and this list of stocks growth stocks (according to analyst forecasts)
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
29 minutes ago
- Yahoo
Wall Street Just Backed a $1B Bitcoin Power Play
Anthony Pompliano is making his biggest play yet. His financial firm, ProCap BTC, is merging with Columbus Circle Capital Corp. I (NASDAQ:CCCM)an SPAC sponsored by a Cohen & Co. subsidiaryto go public and pursue what could be a billion-dollar Bitcoin (BTC-USD) treasury strategy, that could reach up to $1 billion, if fully deployed.. The transaction is backed by $516.5 million in non-voting preferred units via private placement and $235 million in zero-coupon convertible bonds. If completed, the listingslated for before the end of 2025could mark one of the largest institutional Bitcoin holdings outside of Strategy (NASDAQ:MSTR). This move isn't happening in a vacuum. Pompliano is following a path paved by Michael Saylor, whose firm sits on over $60 billion in Bitcoin. He's not alone. In April, Twenty One Capitalbacked by Tetherlocked in $585 million through a SPAC merger with Cantor Equity Partners. And in May, Strive Asset Management, co-founded by Vivek Ramaswamy, signed a reverse merger with Asset Entities Inc. to form another Bitcoin treasury company, with PIPE funding that could raise up to $1.5 billion. What makes Pompliano's push different is the bridge he's buildingbetween Bitcoin's diehards and Wall Street's power players. We feel very fortunate to have the support of both the Bitcoin community and the traditional Wall Street players, he told Bloomberg. The investor list proves it: Magnetar Capital, Woodline Partners LP, Anson Funds, and are in. With a media presence reaching millions, Pompliano may be positioning ProCap BTC as more than just another crypto playit could be Wall Street's next high-conviction bet on digital gold. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
29 minutes ago
- Yahoo
Cathie Wood Pours Millions into AMD, Dumps Circle After 650% Surge
June 23 - Cathie Wood's ARK Invest added to its position in Advanced Micro Devices (NASDAQ:AMD) last week, purchasing 247,753 shares worth about $31.4 million across three ETFs, according to Friday's trade disclosures. The buy was spread across the ARK Innovation (ARKK), ARK Next Generation Internet (ARKW), and ARK Fintech Innovation (ARKF) ETFs, reflecting a continued bet on AI and chipmakers. Wood also picked up 162,255 shares of Airbnb (ABNB) for around $21.4 million and 222,150 shares of Shopify (NASDAQ:SHOP) totaling roughly $23.5 million. Warning! GuruFocus has detected 3 Warning Signs with AMD. In contrast, ARK exited a sizable position in Circle Internet Group (NYSE:CRCL), selling 609,175 shares across its ETFs. The sale totaled nearly $121.6 million and marked the firm's largest trade of the day. Circle stock surged more than 20% Friday and has gained over 650% since its June 5 IPO at $31. The decision to trim the position likely reflects profit-taking after the stock's sharp rally. CRCL is the issuer of the USDC stablecoin and has drawn interest since going public. These trades suggest ARK is leaning into established tech while de-risking from names with elevated valuations after rapid gains. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
31 minutes ago
- Yahoo
Why Quantum Computing Stock Is Plummeting Today
Quantum Computing stock is falling today due to a new share offering and geopolitical risk factors. The company will raise $200 million by selling roughly 14 million shares at a price of $14.25 per share. Stock dilution and geopolitical factors could spur more volatility for the stock in the near term. 10 stocks we like better than Quantum Computing › Quantum Computing (NASDAQ: QUBT) stock is seeing a round of substantial sell-offs in Monday's trading. The company's share price was down 10.6% as of 1 p.m. ET, amid gains of 0.7% for both the S&P 500 (SNPINDEX: ^GSPC) and the Nasdaq Composite (NASDAQINDEX: ^IXIC). Quantum Computing opened today's trading with a valuation pullback due to news that the company is moving to issue and sell new stock. The bearish pressure has intensified following news of rising geopolitical risk factors. Before the market opened this morning, Quantum Computing revealed that it had sold a significant amount of new stock through a private offering. Per the recent announcement, the company will be selling slightly more than 14 million shares of common stock priced at $14.25 per share to a group of institutional investors. The deal is expected to generate $200 million in cash for Quantum Computing, and the company plans to use the funds to accelerate its commercialization initiatives, facilitate potential merger-and-acquisition moves, and strengthen its overall financial footing. The new stock sale is expected to take place around June 24. The announcement of Quantum Computing's upcoming stock sale has understandably raised concerns among investors. Even after a substantial sell-off today, the sale price for the 14 million shares of new stock is still roughly 16% lower than its current trading price. While it's not unusual for companies to offer stock at a discount when selling a large amount of shares through private placement, the deal highlights valuation risks and concerns. In addition to stock dilution from the new share sale, geopolitical dynamics could be a significant source of volatility for Quantum Computing in the near term. Following a U.S. bombing strike on nuclear development facilities in Iran over the weekend, Iran is reportedly responding with missile strikes on U.S. bases in Qatar and Iraq today. As a growth-dependent stock with a speculative outlook, Quantum Computing could see outsized volatility if geopolitical conditions become increasingly unstable. Before you buy stock in Quantum Computing, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Quantum Computing wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $664,089!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $881,731!* Now, it's worth noting Stock Advisor's total average return is 994% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 23, 2025 Keith Noonan has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Why Quantum Computing Stock Is Plummeting Today was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
